Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
FibroGen, Inc. is a leading science-based biopharmaceutical company discovering an...
FibroGen, Inc. is a leading science-based bioph...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...
Exact Sciences Corp. (NASDAQ: EXAS) is committe...
Join the National Investor Network and get the latest information with your interests in mind.